Venture Kick

REMUUN is a biotechnology company focused on revolutionizing the development of therapeutic antibodies. It has created the MEGA platform, which mimics natural antibody gene modification and employs AID-based gene editing. This technology enables clients to accelerate, reduce costs, and enhance precision in the creation of monoclonal antibody therapies.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments

Shape Biopharmaceuticals is a biotechnology company that specializes in the development of immunotherapeutic drugs aimed at treating chronic diseases with limited treatment options. The company focuses on advanced protein design and formulation technologies to create a new generation of immunotherapies. By addressing unmet medical needs, Shape Biopharmaceuticals seeks to improve patient outcomes for individuals with genetically driven conditions who lack effective therapeutic alternatives. Through its innovative healthcare solutions, the company aims to provide hope and enhance treatment possibilities for patients facing significant health challenges.

CellX Biosolutions specializes in sustainable chemical waste management. It offers services such as custom bacterial community biodiscovery and optimization, biodegradability studies, and deployment using microfluidic devices. The company helps industries treat pollutants like PFAS, pharmaceuticals, and microplastics, and enables chemical and pharmaceutical producers to manage their waste cost-effectively and sustainably.

Amporin Pharmaceuticals seeks to create a new class of small-molecule medications that block and eradicate harmful soluble oligomers and holes found within cell membranes.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

Procavea Biotech specializes in developing a drug delivery platform utilizing non-viral protein cages. This innovative technology is tailored specifically for veterinary professionals, aiming to streamline and improve the efficiency of veterinary practice management. By providing a comprehensive solution, Procavea Biotech enhances the overall effectiveness of veterinary services, allowing practitioners to integrate processes seamlessly and elevate the quality of care offered to their clients.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

ASTRA Therapeutics is a medication development company focused on creating innovative therapies for parasitic diseases. Utilizing advanced science and technology, the company develops precision-engineered drugs to combat a wide range of parasitic disorders, including malaria, cryptosporidiosis, and toxoplasmosis. Its mission is to address the global health burden posed by these conditions by bringing effective treatment candidates to market.

metaLead Therapeutics is a biopharmaceutical company focused on developing innovative peptide medications to address metal-related diseases, particularly lead poisoning. The company’s research centers on creating a next-generation treatment that specifically targets and binds lead ions while safeguarding essential metal ions in the body. This targeted approach results in a highly stable medication that can be administered both orally and intravenously. By providing an effective detoxification solution, metaLead Therapeutics aims to improve the health outcomes of individuals affected by lead poisoning on a global scale.

Tandem Therapeutics is a biopharmaceutical company dedicated to pioneering treatments for fibrotic diseases. It focuses on the extracellular matrix, a complex network of proteins that surrounds cells, and develops peptide therapeutics, known as Matrix Targeting Peptides (MTPs), to target and treat the extracellular matrix barrier. This innovative approach aims to provide more precise and effective treatments for patients suffering from fibrotic conditions, including cancers and organ fibrosis.

Aukera Therapeutics is a biotechnology company focused on creating innovative therapeutics for patients afflicted by diseases related to the mTOR protein, including cancer and neurodegenerative disorders. Originating as a spin-off from the Biozentrum of the University of Basel, the company has developed a pharmaceutical drug discovery engine aimed at producing selective inhibitors of the mTOR complex. This technology enables the development of drugs that specifically target various branches of the mTOR signaling pathway, which plays a crucial role in regulating cell growth. By providing targeted treatments, Aukera Therapeutics seeks to improve patient outcomes in the management of mTOR-related diseases.

Biosimo Chemicals is a chemical engineering start-up focused on the development and operation of processes to produce bio-based platform chemicals. The company aims to create sustainable chemical solutions through innovative catalytic reactions and purification processes. Its flagship technology offers a novel method for producing acetic acid, replacing traditional methods that rely on coal and gas with a process that utilizes ethanol derived from biomass and waste. This advancement provides the chemical, pharmaceutical, and materials industries with a direct alternative to fossil-based resources, aligning with global sustainability goals.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.

Biosimo Chemicals is a chemical engineering start-up focused on the development and operation of processes to produce bio-based platform chemicals. The company aims to create sustainable chemical solutions through innovative catalytic reactions and purification processes. Its flagship technology offers a novel method for producing acetic acid, replacing traditional methods that rely on coal and gas with a process that utilizes ethanol derived from biomass and waste. This advancement provides the chemical, pharmaceutical, and materials industries with a direct alternative to fossil-based resources, aligning with global sustainability goals.

NexMR is a Swiss company specializing in nuclear magnetic resonance (NMR) technology to enhance drug discovery processes. It provides key-in-hand solutions that optimize resource use and increase throughput within drug discovery pipelines. The company's platform accelerates screening processes by integrating machine learning for data analysis, enabling efficient exploration of uncharted target spaces. NexMR's proprietary NMR techniques allow for the rapid screening of extensive libraries of molecules, streamlining the evaluation of new compounds and improving the turnaround time for experimental results. Additionally, its technology serves quality control purposes, assisting researchers in determining the content, purity, and molecular structure of chemical samples, which aids healthcare professionals in assessing the viability of potential new drugs.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

ArcoScreen is a Swiss medtech company focused on advancing drug discovery through its innovative microfluidic platform. This platform specializes in drug screening that targets cell membrane receptors, offering a faster and more efficient method for conducting chip-based GPCR assays. By enabling the identification of a drug's mode of action directly on patient cells, ArcoScreen's technology allows for the simultaneous testing of proteins that make up the drugs, assessing their efficacy in a single test. This approach aims to facilitate the treatment of complex diseases such as cancer, Alzheimer's, and diabetes, ultimately enhancing the drug development process for researchers.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

microPow AG, founded in 2018 and located in Meilen, Switzerland, specializes in the manufacture of powders using advanced encapsulation technology and natural ingredients. The company provides an all-natural delivery system for aromas and flavors, significantly enhancing the storability and release of these compounds in various applications. microPow's products cater to a diverse range of sectors, including food, cosmetics, and pharmaceuticals. Their innovative clean-label encapsulation system allows food producers to achieve timed release, minimize losses during production, and ultimately add value to their end products, with offerings that include flavors for coffee, chewing gum, and vegetarian burgers.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

Microcaps AG is a company based in Zurich, Switzerland, founded in 2018, specializing in the development of advanced microencapsulation technology. The firm focuses on creating devices that facilitate the precise production of monodisperse microcapsules and microparticles through innovative microfluidics. Microcaps' solutions are designed to enhance drug delivery systems and probiotic encapsulation, while also providing tailored offerings for various applications, including pharmaceuticals and cosmetics. Their cutting-edge technology enables scalable, fully-automated production that allows for size control, precise dosing, and improved stability of the encapsulated materials. By utilizing a step emulsification device, Microcaps enhances production capacity and throughput rates without compromising quality, making it a pivotal player in the field of microencapsulation.

Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

Prolongate is a protein drugs and biotech company.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

microPow AG, founded in 2018 and located in Meilen, Switzerland, specializes in the manufacture of powders using advanced encapsulation technology and natural ingredients. The company provides an all-natural delivery system for aromas and flavors, significantly enhancing the storability and release of these compounds in various applications. microPow's products cater to a diverse range of sectors, including food, cosmetics, and pharmaceuticals. Their innovative clean-label encapsulation system allows food producers to achieve timed release, minimize losses during production, and ultimately add value to their end products, with offerings that include flavors for coffee, chewing gum, and vegetarian burgers.

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Microcaps AG is a company based in Zurich, Switzerland, founded in 2018, specializing in the development of advanced microencapsulation technology. The firm focuses on creating devices that facilitate the precise production of monodisperse microcapsules and microparticles through innovative microfluidics. Microcaps' solutions are designed to enhance drug delivery systems and probiotic encapsulation, while also providing tailored offerings for various applications, including pharmaceuticals and cosmetics. Their cutting-edge technology enables scalable, fully-automated production that allows for size control, precise dosing, and improved stability of the encapsulated materials. By utilizing a step emulsification device, Microcaps enhances production capacity and throughput rates without compromising quality, making it a pivotal player in the field of microencapsulation.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

microPow AG, founded in 2018 and located in Meilen, Switzerland, specializes in the manufacture of powders using advanced encapsulation technology and natural ingredients. The company provides an all-natural delivery system for aromas and flavors, significantly enhancing the storability and release of these compounds in various applications. microPow's products cater to a diverse range of sectors, including food, cosmetics, and pharmaceuticals. Their innovative clean-label encapsulation system allows food producers to achieve timed release, minimize losses during production, and ultimately add value to their end products, with offerings that include flavors for coffee, chewing gum, and vegetarian burgers.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of innovative healthcare devices. The company has created EmbryoSpin, a device that performs microscopic Nuclear Magnetic Resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold. This groundbreaking device is designed to operate at the scale of a single human embryo, providing a robust and user-friendly solution for researchers. EmbryoSpin facilitates non-invasive embryo viability screening for in-vitro fertilization and enhances biochemical research by allowing detailed chemical analysis of microscopic samples. Annaida Technologies' advancements aim to improve outcomes in reproductive health and deepen understanding in various areas of biochemical research.

Microcaps AG is a company based in Zurich, Switzerland, founded in 2018, specializing in the development of advanced microencapsulation technology. The firm focuses on creating devices that facilitate the precise production of monodisperse microcapsules and microparticles through innovative microfluidics. Microcaps' solutions are designed to enhance drug delivery systems and probiotic encapsulation, while also providing tailored offerings for various applications, including pharmaceuticals and cosmetics. Their cutting-edge technology enables scalable, fully-automated production that allows for size control, precise dosing, and improved stability of the encapsulated materials. By utilizing a step emulsification device, Microcaps enhances production capacity and throughput rates without compromising quality, making it a pivotal player in the field of microencapsulation.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Nagi Bioscience SA is a Swiss company based in Lausanne that specializes in developing and manufacturing an innovative automated testing device utilizing organism-on-chip technology. This device leverages the microscopic worm Caenorhabditis elegans for in vivo testing, enabling pharmaceutical, chemical, and cosmetic companies to assess the toxic and beneficial effects of various substances. By integrating fully automated in vitro handling, culture, and analysis, Nagi Bioscience's platform facilitates toxicity testing, drug discovery, and anthelmintic testing. This approach allows clients to evaluate comprehensive biological responses that can only be observed at the level of the whole organism, thereby transforming traditional testing methodologies.

Lipidon is a bioanalytical service company that specializes in lipid research and lipidomics analytical services. The company focuses on identifying and developing novel biomarkers tailored for the life sciences, cosmetic, and food industries. By providing actionable biomarker discovery, Lipidon aids in precision medicine and various sectors, including pharmaceuticals, biotechnology, cosmetics, and food. The company’s services enable clients to distinguish between products of animal and herbal origin, facilitating informed decision-making in their respective fields.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

ABCDx SA is a privately-funded company based in Geneva, Switzerland, founded in 2014 by three experts in the field of brain biomarkers. The founders include two prominent researchers from the Faculty of Medicine at the University of Geneva and the Vall d’Hebron Research Institute, who are recognized for their contributions to biomarker discovery and validation. The third founder brings extensive experience in the diagnostic and pharmaceutical industries. ABCDx specializes in the development and validation of biomarker and biomarker panel tests aimed at enhancing the diagnosis and treatment of brain injuries. The company's offerings are designed to identify and assess patients at risk of severe long-term complications stemming from traumatic injuries, strokes, and post-stroke infections. Through its innovative approach, ABCDx aims to improve patient outcomes in the realm of brain health.

INOFEA AG is a Swiss biotech company established in 2011, headquartered in Basel. The company specializes in developing patented platform technology that enhances the stability and usability of enzymes for various applications in the pharmaceutical and consumer healthcare sectors. INOFEA's innovative enzyme shielding technology immobilizes and protects fragile enzymes, allowing them to be effectively utilized in in vivo conditions, including digestive health products and personal care items. Additionally, the technology improves industrial biocatalytic processes, addressing the challenges commonly associated with enzyme stability and robustness.

APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Scailyte AG, established in 2017 and headquartered in Sursee, Switzerland, specializes in developing artificial intelligence-based software solutions for analyzing single-cell data. The company's flagship product, ScaiVision, is designed to facilitate the analysis of single-cell data in biomedical research, pharmaceutical discovery, and precision diagnostics. Additionally, Scailyte offers biomarker discovery services, leveraging its unique expertise in single-cell data analysis and AI to identify novel biomarkers defined by disease-associated cell molecular profiles. This innovative approach aims to maximize the success rate for discovering sensitive and robust biomarkers, ultimately enhancing biomedical research and patient care.

MesenFlow Technologies specializes in innovative bio-imaging technology aimed at enhancing drug and cosmetic development. The company’s platform addresses critical challenges in modern drug development, including species cross-reactivity and the ethical concerns of animal testing. By utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and its relevance to human biology. This approach not only accelerates the pharmaceutical testing process but also extends to the cosmetics and nutraceutical sectors, allowing for the assessment of product safety and efficacy at an early stage. MesenFlow's technology is particularly beneficial for organizations requiring animal-free testing solutions, ensuring compliance with regulatory demands while prioritizing human biological impact.

Modum is a Zurich-based startup aims to provide an Internet of Things (IoT)-based supply chain logistics solution to help European companies comply with European Commission regulations for pharmaceutical transport. Modum sensors will record environmental data during shipments to ensure they comply with both supplier-customer contracts and government regulations.

Synple Chem AG, based in Zurich, Switzerland, specializes in the development of automated reagent cartridge-based synthesizers designed to enhance the efficiency of chemical synthesis in laboratories, particularly in drug discovery. Founded in 2016, the company offers products such as Synple 1 and Synple 2, which utilize revolutionary reagent capsules to enable faster and more efficient synthesis of organic compounds. This innovative technology allows researchers, even those with limited chemistry expertise, to conduct complex reactions in a fully automated manner, simplifying the process by minimizing the need for precise measurements and reducing reagent waste. By streamlining the synthesis process, Synple Chem aims to significantly accelerate drug discovery cycles, helping researchers advance their projects more quickly than traditional methods permit.

Modum is a Zurich-based startup aims to provide an Internet of Things (IoT)-based supply chain logistics solution to help European companies comply with European Commission regulations for pharmaceutical transport. Modum sensors will record environmental data during shipments to ensure they comply with both supplier-customer contracts and government regulations.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.

Selmod, located in Basel, Switzerland, specializes in the development of innovative small molecule therapies aimed at treating life-threatening, multi-drug resistant infections. The company is committed to discovering and advancing first-in-class drug candidates that provide second-line and last-resort treatment options for patients in hospital settings, particularly where conventional therapies have failed due to resistance. Selmod's approach includes the development of antibiotics with dual modes of action to effectively counteract existing resistance mechanisms. Its leading candidates, SLM500, SLM100, and SLM300, have demonstrated success in preclinical animal studies and are positioned within a promising market projected to exceed $9 billion. The company aims to capture a substantial market share shortly after entry, supported by a leadership team with extensive experience in clinical development for major pharmaceutical firms. Funding will be utilized to advance SLM500 through IND-enabling studies and to optimize additional lead candidates for further development.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

DermAbiotech develops innovative targeted therapies for acute T cell-mediated inflammatory diseases.

Enzian Pharmaceutics is a manufacturer of pharmaceutical products that specializes in developing oral medications in solid form. The company utilizes a unique cross-ply structure of fibers in its dosage forms, which enables the controlled delivery of drugs into the bloodstream at a consistent rate. This innovative approach allows for a steady concentration of medication within the optimal therapeutic range, facilitating a faster therapeutic response for patients. By providing physicians with effective medications that enhance treatment outcomes, Enzian Pharmaceutics aims to improve patient care and optimize therapeutic efficacy.

Inositec AG, established in 2015 and based in Zurich, Switzerland, is a biotechnology company specializing in the development of novel drugs for soft tissue calcification disorders. It leverages its proprietary Inositune platform, which involves the engineering of inositol phosphate (IP6) analogs by selectively replacing phosphate groups with other chemical groups. This tunable approach enables the creation of molecules with enhanced drug-like properties, tailored for specific therapeutic indications. Inositec's lead programs focus on vascular and renal calcification disorders, including orphan indications, aiming to provide non-antibiotic, toxin-targeted therapies for conditions such as Clostridium difficile infections.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

Enzian Pharmaceutics is a manufacturer of pharmaceutical products that specializes in developing oral medications in solid form. The company utilizes a unique cross-ply structure of fibers in its dosage forms, which enables the controlled delivery of drugs into the bloodstream at a consistent rate. This innovative approach allows for a steady concentration of medication within the optimal therapeutic range, facilitating a faster therapeutic response for patients. By providing physicians with effective medications that enhance treatment outcomes, Enzian Pharmaceutics aims to improve patient care and optimize therapeutic efficacy.

Modum is a Zurich-based startup aims to provide an Internet of Things (IoT)-based supply chain logistics solution to help European companies comply with European Commission regulations for pharmaceutical transport. Modum sensors will record environmental data during shipments to ensure they comply with both supplier-customer contracts and government regulations.

NeuroCycle Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, is a biopharmaceutical company specializing in the development of small molecule drugs that target the nervous system. The company's primary focus is on sub-type selective GABA-A modulation, aiming to deliver next-generation treatments for chronic itch, pain, and certain refractory forms of pediatric epilepsy. Their lead candidate, NCT10004, has demonstrated significant efficacy across various models without causing sedation, immune suppression, dependency/addiction issues, or losing effectiveness over time.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

AlveoliX AG is a Swiss company based in Bern that specializes in drug development by providing innovative in-vitro solutions through its proprietary organ-on-chip technologies. These advanced in-vitro models are designed to closely replicate the human lung environment, significantly enhancing the predictive accuracy of drug responses compared to traditional in-vitro and in-vivo models. By improving preclinical decision-making, AlveoliX aims to streamline the drug discovery process, reduce development costs, and minimize the reliance on animal testing. Its products facilitate a safer and more personalized approach to drug discovery, ultimately helping to identify viable drug candidates more efficiently before clinical trials.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

AlveoliX AG is a Swiss company based in Bern that specializes in drug development by providing innovative in-vitro solutions through its proprietary organ-on-chip technologies. These advanced in-vitro models are designed to closely replicate the human lung environment, significantly enhancing the predictive accuracy of drug responses compared to traditional in-vitro and in-vivo models. By improving preclinical decision-making, AlveoliX aims to streamline the drug discovery process, reduce development costs, and minimize the reliance on animal testing. Its products facilitate a safer and more personalized approach to drug discovery, ultimately helping to identify viable drug candidates more efficiently before clinical trials.

PB&B SA is an early-stage Life Sciences company established in 2013 by a collaboration of bioengineers, plastic surgeons, and scientists. The company focuses on creating natural and minimally invasive solutions for facial aging and body remodeling. PB&B has developed a proprietary injection that enhances adipose (fat) volume in situ through advanced microencapsulation and drug delivery technologies. This innovative approach aims to address underserved needs in the rapidly growing body shaping market, offering a safer and more efficient alternative to traditional fat transfer procedures. The company's products are specifically designed for plastic surgeons and aesthetic injectors involved in body shaping treatments for various applications, including facial, hand, décolleté, and buttock enhancements.

PB&B SA is an early-stage Life Sciences company established in 2013 by a collaboration of bioengineers, plastic surgeons, and scientists. The company focuses on creating natural and minimally invasive solutions for facial aging and body remodeling. PB&B has developed a proprietary injection that enhances adipose (fat) volume in situ through advanced microencapsulation and drug delivery technologies. This innovative approach aims to address underserved needs in the rapidly growing body shaping market, offering a safer and more efficient alternative to traditional fat transfer procedures. The company's products are specifically designed for plastic surgeons and aesthetic injectors involved in body shaping treatments for various applications, including facial, hand, décolleté, and buttock enhancements.

Market Access Companion offers big data-driven decision support for the health and life sciences industries.

Nanolive SA is a Swiss company that specializes in the design and development of advanced imaging devices for live cells. Established in 2013 and headquartered in Ecublens, Switzerland, the company offers the 3D Cell Explorer, a cutting-edge technology that allows researchers to visualize the interior of living cells in three dimensions without the need for labeling or invasive techniques. This innovative device enables detailed observation of various cellular processes such as cell division, organelle structure, cell morphology, differentiation, and interactions between cells. By capturing unbiased live cell data, Nanolive's technology supports the research and development of new drugs and therapies, facilitating quality analysis and providing valuable biological insights for scientists and researchers in the field of life sciences.

PB&B SA is an early-stage Life Sciences company established in 2013 by a collaboration of bioengineers, plastic surgeons, and scientists. The company focuses on creating natural and minimally invasive solutions for facial aging and body remodeling. PB&B has developed a proprietary injection that enhances adipose (fat) volume in situ through advanced microencapsulation and drug delivery technologies. This innovative approach aims to address underserved needs in the rapidly growing body shaping market, offering a safer and more efficient alternative to traditional fat transfer procedures. The company's products are specifically designed for plastic surgeons and aesthetic injectors involved in body shaping treatments for various applications, including facial, hand, décolleté, and buttock enhancements.

TransCure BioServices SAS is a biotechnology company based in Archamps, France, founded in 2012. The company specializes in vivo pharmacology preclinical services and offers unique research and development platforms, including its Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These innovative models are designed to enhance the drug profiling and development process for pharmaceutical companies, biotech firms, and academic researchers focusing on immuno-related diseases and anti-HIV/AIDS therapies. By providing access to its specialized platforms as fee-for-service offerings, TransCure BioServices enables clients to efficiently generate and characterize humanized mouse models that deliver predictive insights into human drug responses. This capability helps accelerate the development and commercialization of new therapies, ultimately allowing clients to bring effective treatments to market more quickly and cost-effectively.